Global Macrolide Antibiotics

Macrolide Antibiotics Comprehensive Study by Type (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin), Application (Ear, Nose and Throat Infections, Chest Infections, Skin Infections, Mouth and Dental Infections, Sexually Transmitted Infections), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), End-user (Hospitals, Clinics, Ambulatory Surgical Centres, Research Laboratories) Players and Region - Global Market Outlook to 2026

Macrolide Antibiotics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Macrolide Antibiotics Market?

Macrolide antibiotics are a particular type of antibiotic that inhibits the growth of bacteria by preventing them from being able to produce proteins that are essential for their growth. These antibiotics used to treat, and sometimes prevent, a wide variety of bacterial infections. Macrolide antibiotics are azithromycin, clarithromycin, erythromycin, spiramycin, and telithromycin. These antibiotics are only effective in treating bacterial infections associated with conditions such as ear, nose, and throat infections, chest infections, skin infections, sexually transmitted diseases, mouth, and dental infections. Macrolide antibiotics may be prescribed to prevent a certain type of bacterial infection and can be used as an alternative to penicillin antibiotics.

The market study is being classified by Type (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), by Application (Ear, Nose and Throat Infections, Chest Infections, Skin Infections, Mouth and Dental Infections and Sexually Transmitted Infections) and major geographies with country level break-up.

Macrolide Pharmaceuticals (United States), Teva Pharmaceutical Industries Ltd. (Israel), Merck Sharp & Dohme Corp (United States), Pfizer Inc. (United States), Aurobindo Pharma Limited (India), Neo Química (Brazil), Fresenius Kabi USA (United States), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (United States) and WOCKHARDT (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Alembic Pharmaceuticals Ltd (India), Bionpharma Inc. (United States) and Novartis International AG (Switzerland).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Macrolide Antibiotics market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Macrolide Antibiotics market by Type, Application and Region.

On the basis of geography, the market of Macrolide Antibiotics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Bacterial Infections
  • Rise in the Number of Hospitals and Clinics

Market Trend
  • Increased Research and Development Investments

Restraints
  • Side Effects of the Macrolide Antibiotics

Opportunities
  • Growth in the Healthcare Industry
  • Huge Investments by Major Players in the Market

Challenges
  • Stringent Government Rules and Regulations


In January 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the availability of a generic version of NuvaRing (etonogestrel and Ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.


Key Target Audience
Macrolide Antibiotics Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Azithromycin
  • Clarithromycin
  • Erythromycin
  • Fidaxomicin
  • Telithromycin
By Application
  • Ear, Nose and Throat Infections
  • Chest Infections
  • Skin Infections
  • Mouth and Dental Infections
  • Sexually Transmitted Infections
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By End-user
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Research Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Bacterial Infections
      • 3.2.2. Rise in the Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Investments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Macrolide Antibiotics, by Type, Application, Distribution Channel, End-user and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Macrolide Antibiotics (Value)
      • 5.2.1. Global Macrolide Antibiotics by: Type (Value)
        • 5.2.1.1. Azithromycin
        • 5.2.1.2. Clarithromycin
        • 5.2.1.3. Erythromycin
        • 5.2.1.4. Fidaxomicin
        • 5.2.1.5. Telithromycin
      • 5.2.2. Global Macrolide Antibiotics by: Application (Value)
        • 5.2.2.1. Ear, Nose and Throat Infections
        • 5.2.2.2. Chest Infections
        • 5.2.2.3. Skin Infections
        • 5.2.2.4. Mouth and Dental Infections
        • 5.2.2.5. Sexually Transmitted Infections
      • 5.2.3. Global Macrolide Antibiotics by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Macrolide Antibiotics by: End-user (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Ambulatory Surgical Centres
        • 5.2.4.4. Research Laboratories
      • 5.2.5. Global Macrolide Antibiotics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Macrolide Antibiotics (Volume)
      • 5.3.1. Global Macrolide Antibiotics by: Type (Volume)
        • 5.3.1.1. Azithromycin
        • 5.3.1.2. Clarithromycin
        • 5.3.1.3. Erythromycin
        • 5.3.1.4. Fidaxomicin
        • 5.3.1.5. Telithromycin
      • 5.3.2. Global Macrolide Antibiotics by: Application (Volume)
        • 5.3.2.1. Ear, Nose and Throat Infections
        • 5.3.2.2. Chest Infections
        • 5.3.2.3. Skin Infections
        • 5.3.2.4. Mouth and Dental Infections
        • 5.3.2.5. Sexually Transmitted Infections
      • 5.3.3. Global Macrolide Antibiotics by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online
        • 5.3.3.4. Others
      • 5.3.4. Global Macrolide Antibiotics by: End-user (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Clinics
        • 5.3.4.3. Ambulatory Surgical Centres
        • 5.3.4.4. Research Laboratories
      • 5.3.5. Global Macrolide Antibiotics Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Macrolide Antibiotics (Price)
      • 5.4.1. Global Macrolide Antibiotics by: Type (Price)
  • 6. Macrolide Antibiotics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Macrolide Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck Sharp & Dohme Corp (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Aurobindo Pharma Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Neo Química (Brazil)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius Kabi USA (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sandoz International GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Gland Pharma Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. WOCKHARDT (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Macrolide Antibiotics Sale, by Type, Application, Distribution Channel, End-user and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Macrolide Antibiotics (Value)
      • 7.2.1. Global Macrolide Antibiotics by: Type (Value)
        • 7.2.1.1. Azithromycin
        • 7.2.1.2. Clarithromycin
        • 7.2.1.3. Erythromycin
        • 7.2.1.4. Fidaxomicin
        • 7.2.1.5. Telithromycin
      • 7.2.2. Global Macrolide Antibiotics by: Application (Value)
        • 7.2.2.1. Ear, Nose and Throat Infections
        • 7.2.2.2. Chest Infections
        • 7.2.2.3. Skin Infections
        • 7.2.2.4. Mouth and Dental Infections
        • 7.2.2.5. Sexually Transmitted Infections
      • 7.2.3. Global Macrolide Antibiotics by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Macrolide Antibiotics by: End-user (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Ambulatory Surgical Centres
        • 7.2.4.4. Research Laboratories
      • 7.2.5. Global Macrolide Antibiotics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Macrolide Antibiotics (Volume)
      • 7.3.1. Global Macrolide Antibiotics by: Type (Volume)
        • 7.3.1.1. Azithromycin
        • 7.3.1.2. Clarithromycin
        • 7.3.1.3. Erythromycin
        • 7.3.1.4. Fidaxomicin
        • 7.3.1.5. Telithromycin
      • 7.3.2. Global Macrolide Antibiotics by: Application (Volume)
        • 7.3.2.1. Ear, Nose and Throat Infections
        • 7.3.2.2. Chest Infections
        • 7.3.2.3. Skin Infections
        • 7.3.2.4. Mouth and Dental Infections
        • 7.3.2.5. Sexually Transmitted Infections
      • 7.3.3. Global Macrolide Antibiotics by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online
        • 7.3.3.4. Others
      • 7.3.4. Global Macrolide Antibiotics by: End-user (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Clinics
        • 7.3.4.3. Ambulatory Surgical Centres
        • 7.3.4.4. Research Laboratories
      • 7.3.5. Global Macrolide Antibiotics Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Macrolide Antibiotics (Price)
      • 7.4.1. Global Macrolide Antibiotics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Macrolide Antibiotics: by Type(USD Million)
  • Table 2. Macrolide Antibiotics Azithromycin , by Region USD Million (2015-2020)
  • Table 3. Macrolide Antibiotics Clarithromycin , by Region USD Million (2015-2020)
  • Table 4. Macrolide Antibiotics Erythromycin , by Region USD Million (2015-2020)
  • Table 5. Macrolide Antibiotics Fidaxomicin , by Region USD Million (2015-2020)
  • Table 6. Macrolide Antibiotics Telithromycin , by Region USD Million (2015-2020)
  • Table 7. Macrolide Antibiotics: by Application(USD Million)
  • Table 8. Macrolide Antibiotics Ear, Nose and Throat Infections , by Region USD Million (2015-2020)
  • Table 9. Macrolide Antibiotics Chest Infections , by Region USD Million (2015-2020)
  • Table 10. Macrolide Antibiotics Skin Infections , by Region USD Million (2015-2020)
  • Table 11. Macrolide Antibiotics Mouth and Dental Infections , by Region USD Million (2015-2020)
  • Table 12. Macrolide Antibiotics Sexually Transmitted Infections , by Region USD Million (2015-2020)
  • Table 13. Macrolide Antibiotics: by Distribution Channel(USD Million)
  • Table 14. Macrolide Antibiotics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Macrolide Antibiotics Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Macrolide Antibiotics Online , by Region USD Million (2015-2020)
  • Table 17. Macrolide Antibiotics Others , by Region USD Million (2015-2020)
  • Table 18. Macrolide Antibiotics: by End-user(USD Million)
  • Table 19. Macrolide Antibiotics Hospitals , by Region USD Million (2015-2020)
  • Table 20. Macrolide Antibiotics Clinics , by Region USD Million (2015-2020)
  • Table 21. Macrolide Antibiotics Ambulatory Surgical Centres , by Region USD Million (2015-2020)
  • Table 22. Macrolide Antibiotics Research Laboratories , by Region USD Million (2015-2020)
  • Table 23. South America Macrolide Antibiotics, by Country USD Million (2015-2020)
  • Table 24. South America Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 25. South America Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 26. South America Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 27. South America Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 28. Brazil Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 29. Brazil Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 30. Brazil Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 31. Brazil Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 32. Argentina Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 33. Argentina Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 34. Argentina Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 35. Argentina Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 36. Rest of South America Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 37. Rest of South America Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 38. Rest of South America Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 39. Rest of South America Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 40. Asia Pacific Macrolide Antibiotics, by Country USD Million (2015-2020)
  • Table 41. Asia Pacific Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 42. Asia Pacific Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 43. Asia Pacific Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 44. Asia Pacific Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 45. China Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 46. China Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 47. China Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 48. China Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 49. Japan Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 50. Japan Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 51. Japan Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 52. Japan Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 53. India Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 54. India Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 55. India Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 56. India Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 57. South Korea Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 58. South Korea Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 59. South Korea Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 60. South Korea Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 61. Taiwan Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 62. Taiwan Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 63. Taiwan Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 64. Taiwan Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 65. Australia Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 66. Australia Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 67. Australia Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 68. Australia Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 73. Europe Macrolide Antibiotics, by Country USD Million (2015-2020)
  • Table 74. Europe Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 75. Europe Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 76. Europe Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 77. Europe Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 78. Germany Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 79. Germany Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 80. Germany Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 81. Germany Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 82. France Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 83. France Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 84. France Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 85. France Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 86. Italy Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 87. Italy Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 88. Italy Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 89. Italy Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 90. United Kingdom Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 91. United Kingdom Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 92. United Kingdom Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 93. United Kingdom Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 94. Netherlands Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 95. Netherlands Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 96. Netherlands Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 97. Netherlands Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 98. Rest of Europe Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 99. Rest of Europe Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 100. Rest of Europe Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 101. Rest of Europe Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 102. MEA Macrolide Antibiotics, by Country USD Million (2015-2020)
  • Table 103. MEA Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 104. MEA Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 105. MEA Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 106. MEA Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 107. Middle East Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 108. Middle East Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 109. Middle East Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 110. Middle East Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 111. Africa Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 112. Africa Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 113. Africa Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 114. Africa Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 115. North America Macrolide Antibiotics, by Country USD Million (2015-2020)
  • Table 116. North America Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 117. North America Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 118. North America Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 119. North America Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 120. United States Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 121. United States Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 122. United States Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 123. United States Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 124. Canada Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 125. Canada Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 126. Canada Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 127. Canada Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 128. Mexico Macrolide Antibiotics, by Type USD Million (2015-2020)
  • Table 129. Mexico Macrolide Antibiotics, by Application USD Million (2015-2020)
  • Table 130. Mexico Macrolide Antibiotics, by Distribution Channel USD Million (2015-2020)
  • Table 131. Mexico Macrolide Antibiotics, by End-user USD Million (2015-2020)
  • Table 132. Macrolide Antibiotics Sales: by Type(K Units)
  • Table 133. Macrolide Antibiotics Sales Azithromycin , by Region K Units (2015-2020)
  • Table 134. Macrolide Antibiotics Sales Clarithromycin , by Region K Units (2015-2020)
  • Table 135. Macrolide Antibiotics Sales Erythromycin , by Region K Units (2015-2020)
  • Table 136. Macrolide Antibiotics Sales Fidaxomicin , by Region K Units (2015-2020)
  • Table 137. Macrolide Antibiotics Sales Telithromycin , by Region K Units (2015-2020)
  • Table 138. Macrolide Antibiotics Sales: by Application(K Units)
  • Table 139. Macrolide Antibiotics Sales Ear, Nose and Throat Infections , by Region K Units (2015-2020)
  • Table 140. Macrolide Antibiotics Sales Chest Infections , by Region K Units (2015-2020)
  • Table 141. Macrolide Antibiotics Sales Skin Infections , by Region K Units (2015-2020)
  • Table 142. Macrolide Antibiotics Sales Mouth and Dental Infections , by Region K Units (2015-2020)
  • Table 143. Macrolide Antibiotics Sales Sexually Transmitted Infections , by Region K Units (2015-2020)
  • Table 144. Macrolide Antibiotics Sales: by Distribution Channel(K Units)
  • Table 145. Macrolide Antibiotics Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 146. Macrolide Antibiotics Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 147. Macrolide Antibiotics Sales Online , by Region K Units (2015-2020)
  • Table 148. Macrolide Antibiotics Sales Others , by Region K Units (2015-2020)
  • Table 149. Macrolide Antibiotics Sales: by End-user(K Units)
  • Table 150. Macrolide Antibiotics Sales Hospitals , by Region K Units (2015-2020)
  • Table 151. Macrolide Antibiotics Sales Clinics , by Region K Units (2015-2020)
  • Table 152. Macrolide Antibiotics Sales Ambulatory Surgical Centres , by Region K Units (2015-2020)
  • Table 153. Macrolide Antibiotics Sales Research Laboratories , by Region K Units (2015-2020)
  • Table 154. South America Macrolide Antibiotics Sales, by Country K Units (2015-2020)
  • Table 155. South America Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 156. South America Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 157. South America Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 158. South America Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 159. Brazil Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 160. Brazil Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 161. Brazil Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 162. Brazil Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 163. Argentina Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 164. Argentina Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 165. Argentina Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 166. Argentina Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 167. Rest of South America Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 168. Rest of South America Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 169. Rest of South America Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 170. Rest of South America Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 171. Asia Pacific Macrolide Antibiotics Sales, by Country K Units (2015-2020)
  • Table 172. Asia Pacific Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 173. Asia Pacific Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 174. Asia Pacific Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 175. Asia Pacific Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 176. China Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 177. China Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 178. China Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 179. China Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 180. Japan Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 181. Japan Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 182. Japan Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 183. Japan Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 184. India Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 185. India Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 186. India Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 187. India Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 188. South Korea Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 189. South Korea Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 190. South Korea Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 191. South Korea Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 192. Taiwan Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 193. Taiwan Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 194. Taiwan Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 195. Taiwan Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 196. Australia Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 197. Australia Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 198. Australia Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 199. Australia Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 200. Rest of Asia-Pacific Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 201. Rest of Asia-Pacific Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 202. Rest of Asia-Pacific Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 203. Rest of Asia-Pacific Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 204. Europe Macrolide Antibiotics Sales, by Country K Units (2015-2020)
  • Table 205. Europe Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 206. Europe Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 207. Europe Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 208. Europe Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 209. Germany Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 210. Germany Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 211. Germany Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 212. Germany Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 213. France Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 214. France Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 215. France Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 216. France Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 217. Italy Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 218. Italy Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 219. Italy Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 220. Italy Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 221. United Kingdom Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 222. United Kingdom Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 223. United Kingdom Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 224. United Kingdom Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 225. Netherlands Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 226. Netherlands Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 227. Netherlands Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 228. Netherlands Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 229. Rest of Europe Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 230. Rest of Europe Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 231. Rest of Europe Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 232. Rest of Europe Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 233. MEA Macrolide Antibiotics Sales, by Country K Units (2015-2020)
  • Table 234. MEA Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 235. MEA Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 236. MEA Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 237. MEA Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 238. Middle East Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 239. Middle East Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 240. Middle East Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 241. Middle East Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 242. Africa Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 243. Africa Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 244. Africa Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 245. Africa Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 246. North America Macrolide Antibiotics Sales, by Country K Units (2015-2020)
  • Table 247. North America Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 248. North America Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 249. North America Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 250. North America Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 251. United States Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 252. United States Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 253. United States Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 254. United States Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 255. Canada Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 256. Canada Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 257. Canada Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 258. Canada Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 259. Mexico Macrolide Antibiotics Sales, by Type K Units (2015-2020)
  • Table 260. Mexico Macrolide Antibiotics Sales, by Application K Units (2015-2020)
  • Table 261. Mexico Macrolide Antibiotics Sales, by Distribution Channel K Units (2015-2020)
  • Table 262. Mexico Macrolide Antibiotics Sales, by End-user K Units (2015-2020)
  • Table 263. Macrolide Antibiotics: by Type(USD/Units)
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Macrolide Antibiotics: by Type(USD Million)
  • Table 276. Macrolide Antibiotics Azithromycin , by Region USD Million (2021-2026)
  • Table 277. Macrolide Antibiotics Clarithromycin , by Region USD Million (2021-2026)
  • Table 278. Macrolide Antibiotics Erythromycin , by Region USD Million (2021-2026)
  • Table 279. Macrolide Antibiotics Fidaxomicin , by Region USD Million (2021-2026)
  • Table 280. Macrolide Antibiotics Telithromycin , by Region USD Million (2021-2026)
  • Table 281. Macrolide Antibiotics: by Application(USD Million)
  • Table 282. Macrolide Antibiotics Ear, Nose and Throat Infections , by Region USD Million (2021-2026)
  • Table 283. Macrolide Antibiotics Chest Infections , by Region USD Million (2021-2026)
  • Table 284. Macrolide Antibiotics Skin Infections , by Region USD Million (2021-2026)
  • Table 285. Macrolide Antibiotics Mouth and Dental Infections , by Region USD Million (2021-2026)
  • Table 286. Macrolide Antibiotics Sexually Transmitted Infections , by Region USD Million (2021-2026)
  • Table 287. Macrolide Antibiotics: by Distribution Channel(USD Million)
  • Table 288. Macrolide Antibiotics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 289. Macrolide Antibiotics Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 290. Macrolide Antibiotics Online , by Region USD Million (2021-2026)
  • Table 291. Macrolide Antibiotics Others , by Region USD Million (2021-2026)
  • Table 292. Macrolide Antibiotics: by End-user(USD Million)
  • Table 293. Macrolide Antibiotics Hospitals , by Region USD Million (2021-2026)
  • Table 294. Macrolide Antibiotics Clinics , by Region USD Million (2021-2026)
  • Table 295. Macrolide Antibiotics Ambulatory Surgical Centres , by Region USD Million (2021-2026)
  • Table 296. Macrolide Antibiotics Research Laboratories , by Region USD Million (2021-2026)
  • Table 297. South America Macrolide Antibiotics, by Country USD Million (2021-2026)
  • Table 298. South America Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 299. South America Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 300. South America Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 301. South America Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 302. Brazil Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 303. Brazil Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 304. Brazil Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 305. Brazil Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 306. Argentina Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 307. Argentina Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 308. Argentina Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 309. Argentina Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 310. Rest of South America Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 311. Rest of South America Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 312. Rest of South America Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 313. Rest of South America Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 314. Asia Pacific Macrolide Antibiotics, by Country USD Million (2021-2026)
  • Table 315. Asia Pacific Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 316. Asia Pacific Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 317. Asia Pacific Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 318. Asia Pacific Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 319. China Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 320. China Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 321. China Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 322. China Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 323. Japan Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 324. Japan Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 325. Japan Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 326. Japan Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 327. India Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 328. India Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 329. India Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 330. India Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 331. South Korea Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 332. South Korea Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 333. South Korea Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 334. South Korea Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 335. Taiwan Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 336. Taiwan Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 337. Taiwan Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 338. Taiwan Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 339. Australia Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 340. Australia Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 341. Australia Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 342. Australia Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 343. Rest of Asia-Pacific Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 344. Rest of Asia-Pacific Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 345. Rest of Asia-Pacific Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 346. Rest of Asia-Pacific Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 347. Europe Macrolide Antibiotics, by Country USD Million (2021-2026)
  • Table 348. Europe Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 349. Europe Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 350. Europe Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 351. Europe Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 352. Germany Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 353. Germany Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 354. Germany Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 355. Germany Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 356. France Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 357. France Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 358. France Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 359. France Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 360. Italy Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 361. Italy Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 362. Italy Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 363. Italy Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 364. United Kingdom Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 365. United Kingdom Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 366. United Kingdom Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 367. United Kingdom Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 368. Netherlands Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 369. Netherlands Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 370. Netherlands Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 371. Netherlands Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 372. Rest of Europe Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 373. Rest of Europe Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 374. Rest of Europe Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 375. Rest of Europe Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 376. MEA Macrolide Antibiotics, by Country USD Million (2021-2026)
  • Table 377. MEA Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 378. MEA Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 379. MEA Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 380. MEA Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 381. Middle East Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 382. Middle East Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 383. Middle East Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 384. Middle East Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 385. Africa Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 386. Africa Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 387. Africa Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 388. Africa Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 389. North America Macrolide Antibiotics, by Country USD Million (2021-2026)
  • Table 390. North America Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 391. North America Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 392. North America Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 393. North America Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 394. United States Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 395. United States Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 396. United States Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 397. United States Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 398. Canada Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 399. Canada Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 400. Canada Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 401. Canada Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 402. Mexico Macrolide Antibiotics, by Type USD Million (2021-2026)
  • Table 403. Mexico Macrolide Antibiotics, by Application USD Million (2021-2026)
  • Table 404. Mexico Macrolide Antibiotics, by Distribution Channel USD Million (2021-2026)
  • Table 405. Mexico Macrolide Antibiotics, by End-user USD Million (2021-2026)
  • Table 406. Macrolide Antibiotics Sales: by Type(K Units)
  • Table 407. Macrolide Antibiotics Sales Azithromycin , by Region K Units (2021-2026)
  • Table 408. Macrolide Antibiotics Sales Clarithromycin , by Region K Units (2021-2026)
  • Table 409. Macrolide Antibiotics Sales Erythromycin , by Region K Units (2021-2026)
  • Table 410. Macrolide Antibiotics Sales Fidaxomicin , by Region K Units (2021-2026)
  • Table 411. Macrolide Antibiotics Sales Telithromycin , by Region K Units (2021-2026)
  • Table 412. Macrolide Antibiotics Sales: by Application(K Units)
  • Table 413. Macrolide Antibiotics Sales Ear, Nose and Throat Infections , by Region K Units (2021-2026)
  • Table 414. Macrolide Antibiotics Sales Chest Infections , by Region K Units (2021-2026)
  • Table 415. Macrolide Antibiotics Sales Skin Infections , by Region K Units (2021-2026)
  • Table 416. Macrolide Antibiotics Sales Mouth and Dental Infections , by Region K Units (2021-2026)
  • Table 417. Macrolide Antibiotics Sales Sexually Transmitted Infections , by Region K Units (2021-2026)
  • Table 418. Macrolide Antibiotics Sales: by Distribution Channel(K Units)
  • Table 419. Macrolide Antibiotics Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 420. Macrolide Antibiotics Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 421. Macrolide Antibiotics Sales Online , by Region K Units (2021-2026)
  • Table 422. Macrolide Antibiotics Sales Others , by Region K Units (2021-2026)
  • Table 423. Macrolide Antibiotics Sales: by End-user(K Units)
  • Table 424. Macrolide Antibiotics Sales Hospitals , by Region K Units (2021-2026)
  • Table 425. Macrolide Antibiotics Sales Clinics , by Region K Units (2021-2026)
  • Table 426. Macrolide Antibiotics Sales Ambulatory Surgical Centres , by Region K Units (2021-2026)
  • Table 427. Macrolide Antibiotics Sales Research Laboratories , by Region K Units (2021-2026)
  • Table 428. South America Macrolide Antibiotics Sales, by Country K Units (2021-2026)
  • Table 429. South America Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 430. South America Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 431. South America Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 432. South America Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 433. Brazil Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 434. Brazil Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 435. Brazil Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 436. Brazil Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 437. Argentina Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 438. Argentina Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 439. Argentina Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 440. Argentina Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 441. Rest of South America Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 442. Rest of South America Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 443. Rest of South America Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 444. Rest of South America Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 445. Asia Pacific Macrolide Antibiotics Sales, by Country K Units (2021-2026)
  • Table 446. Asia Pacific Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 447. Asia Pacific Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 448. Asia Pacific Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 449. Asia Pacific Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 450. China Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 451. China Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 452. China Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 453. China Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 454. Japan Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 455. Japan Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 456. Japan Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 457. Japan Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 458. India Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 459. India Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 460. India Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 461. India Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 462. South Korea Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 463. South Korea Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 464. South Korea Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 465. South Korea Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 466. Taiwan Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 467. Taiwan Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 468. Taiwan Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 469. Taiwan Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 470. Australia Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 471. Australia Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 472. Australia Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 473. Australia Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 474. Rest of Asia-Pacific Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 475. Rest of Asia-Pacific Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 476. Rest of Asia-Pacific Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 477. Rest of Asia-Pacific Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 478. Europe Macrolide Antibiotics Sales, by Country K Units (2021-2026)
  • Table 479. Europe Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 480. Europe Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 481. Europe Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 482. Europe Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 483. Germany Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 484. Germany Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 485. Germany Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 486. Germany Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 487. France Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 488. France Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 489. France Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 490. France Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 491. Italy Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 492. Italy Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 493. Italy Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 494. Italy Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 495. United Kingdom Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 496. United Kingdom Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 497. United Kingdom Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 498. United Kingdom Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 499. Netherlands Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 500. Netherlands Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 501. Netherlands Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 502. Netherlands Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 503. Rest of Europe Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 504. Rest of Europe Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 505. Rest of Europe Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 506. Rest of Europe Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 507. MEA Macrolide Antibiotics Sales, by Country K Units (2021-2026)
  • Table 508. MEA Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 509. MEA Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 510. MEA Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 511. MEA Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 512. Middle East Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 513. Middle East Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 514. Middle East Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 515. Middle East Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 516. Africa Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 517. Africa Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 518. Africa Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 519. Africa Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 520. North America Macrolide Antibiotics Sales, by Country K Units (2021-2026)
  • Table 521. North America Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 522. North America Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 523. North America Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 524. North America Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 525. United States Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 526. United States Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 527. United States Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 528. United States Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 529. Canada Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 530. Canada Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 531. Canada Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 532. Canada Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 533. Mexico Macrolide Antibiotics Sales, by Type K Units (2021-2026)
  • Table 534. Mexico Macrolide Antibiotics Sales, by Application K Units (2021-2026)
  • Table 535. Mexico Macrolide Antibiotics Sales, by Distribution Channel K Units (2021-2026)
  • Table 536. Mexico Macrolide Antibiotics Sales, by End-user K Units (2021-2026)
  • Table 537. Macrolide Antibiotics: by Type(USD/Units)
  • Table 538. Research Programs/Design for This Report
  • Table 539. Key Data Information from Secondary Sources
  • Table 540. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Macrolide Antibiotics: by Type USD Million (2015-2020)
  • Figure 5. Global Macrolide Antibiotics: by Application USD Million (2015-2020)
  • Figure 6. Global Macrolide Antibiotics: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Macrolide Antibiotics: by End-user USD Million (2015-2020)
  • Figure 8. South America Macrolide Antibiotics Share (%), by Country
  • Figure 9. Asia Pacific Macrolide Antibiotics Share (%), by Country
  • Figure 10. Europe Macrolide Antibiotics Share (%), by Country
  • Figure 11. MEA Macrolide Antibiotics Share (%), by Country
  • Figure 12. North America Macrolide Antibiotics Share (%), by Country
  • Figure 13. Global Macrolide Antibiotics: by Type K Units (2015-2020)
  • Figure 14. Global Macrolide Antibiotics: by Application K Units (2015-2020)
  • Figure 15. Global Macrolide Antibiotics: by Distribution Channel K Units (2015-2020)
  • Figure 16. Global Macrolide Antibiotics: by End-user K Units (2015-2020)
  • Figure 17. South America Macrolide Antibiotics Share (%), by Country
  • Figure 18. Asia Pacific Macrolide Antibiotics Share (%), by Country
  • Figure 19. Europe Macrolide Antibiotics Share (%), by Country
  • Figure 20. MEA Macrolide Antibiotics Share (%), by Country
  • Figure 21. North America Macrolide Antibiotics Share (%), by Country
  • Figure 22. Global Macrolide Antibiotics: by Type USD/Units (2015-2020)
  • Figure 23. Global Macrolide Antibiotics share by Players 2020 (%)
  • Figure 24. Global Macrolide Antibiotics share by Players (Top 3) 2020(%)
  • Figure 25. Global Macrolide Antibiotics share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Macrolide Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 28. Macrolide Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 31. Merck Sharp & Dohme Corp (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck Sharp & Dohme Corp (United States) Revenue: by Geography 2020
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Aurobindo Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 36. Aurobindo Pharma Limited (India) Revenue: by Geography 2020
  • Figure 37. Neo Química (Brazil) Revenue, Net Income and Gross profit
  • Figure 38. Neo Química (Brazil) Revenue: by Geography 2020
  • Figure 39. Fresenius Kabi USA (United States) Revenue, Net Income and Gross profit
  • Figure 40. Fresenius Kabi USA (United States) Revenue: by Geography 2020
  • Figure 41. Sandoz International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Sandoz International GmbH (Germany) Revenue: by Geography 2020
  • Figure 43. Gland Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 44. Gland Pharma Limited (India) Revenue: by Geography 2020
  • Figure 45. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 47. WOCKHARDT (United States) Revenue, Net Income and Gross profit
  • Figure 48. WOCKHARDT (United States) Revenue: by Geography 2020
  • Figure 49. Global Macrolide Antibiotics: by Type USD Million (2021-2026)
  • Figure 50. Global Macrolide Antibiotics: by Application USD Million (2021-2026)
  • Figure 51. Global Macrolide Antibiotics: by Distribution Channel USD Million (2021-2026)
  • Figure 52. Global Macrolide Antibiotics: by End-user USD Million (2021-2026)
  • Figure 53. South America Macrolide Antibiotics Share (%), by Country
  • Figure 54. Asia Pacific Macrolide Antibiotics Share (%), by Country
  • Figure 55. Europe Macrolide Antibiotics Share (%), by Country
  • Figure 56. MEA Macrolide Antibiotics Share (%), by Country
  • Figure 57. North America Macrolide Antibiotics Share (%), by Country
  • Figure 58. Global Macrolide Antibiotics: by Type K Units (2021-2026)
  • Figure 59. Global Macrolide Antibiotics: by Application K Units (2021-2026)
  • Figure 60. Global Macrolide Antibiotics: by Distribution Channel K Units (2021-2026)
  • Figure 61. Global Macrolide Antibiotics: by End-user K Units (2021-2026)
  • Figure 62. South America Macrolide Antibiotics Share (%), by Country
  • Figure 63. Asia Pacific Macrolide Antibiotics Share (%), by Country
  • Figure 64. Europe Macrolide Antibiotics Share (%), by Country
  • Figure 65. MEA Macrolide Antibiotics Share (%), by Country
  • Figure 66. North America Macrolide Antibiotics Share (%), by Country
  • Figure 67. Global Macrolide Antibiotics: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Macrolide Pharmaceuticals (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Merck Sharp & Dohme Corp (United States)
  • Pfizer Inc. (United States)
  • Aurobindo Pharma Limited (India)
  • Neo Química (Brazil)
  • Fresenius Kabi USA (United States)
  • Sandoz International GmbH (Germany)
  • Gland Pharma Limited (India)
  • Mylan N.V. (United States)
  • WOCKHARDT (United States)
Additional players considered in the study are as follows:
Alembic Pharmaceuticals Ltd (India) , Bionpharma Inc. (United States) , Novartis International AG (Switzerland)
Select User Access Type

Key Highlights of Report


Feb 2021 236 Pages 90 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Macrolide Antibiotics Quantitative research analysis
Global Macrolide Antibiotics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Bacterial Infections " is seen as one of major growth factors of Macrolide Antibiotics Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Macrolide Antibiotics Report?

Have a Query? Click Here

Other Related Reports

Athlete's Foot Drugs Comprehensive Study by Type (OTC Medications (miconazole, terbinafine, clotrimazole, butenafine and tolnaftate), Prescription Medications (itraconazole, fluconazole, prescription...
$ 3750
Medical Morphine Comprehensive Study by Type (Tablets, Capsule, Injectable), Application (Anesthesia, Cough Suppressant, Diarrhea Suppressant, Other), Distribution Chanel (Online, Offline) Players an...
$ 3500
Mometasone Furoate Ointment Comprehensive Study by Type (10g/Box, 15g/Box), Application (Eczema, Dermatitis, Allergies, Rash), Distribution Channel (Online, Medical Stores, Super Markets, Specialty S...
$ 3450
Detox Product Comprehensive Study by Type (Pharmaceuticals, Food Supplement, Cosmetics), Application (Supermarket, Convenience Stores, Specialty Stores, Online Stores, Other), Origin (Organic, Conven...
$ 3450
Type 1 Diabetes Drugs Comprehensive Study by Type (Insulins, Symlin), Intake Duration (Split or mixed, Split or mixed variant, Multiple daily injections (MDI), Continuous subcutaneous insulin infusio...
$ 3650
Arthritis Drug Comprehensive Study by Type (Synthetic DMARDs, Biological DMARDs, NSAIDs, Corticosteroids, Analgesics), Application (Retail Pharmacies, Hospital Pharmacies, Drug Stores, E-Commerce), R...
$ 3750